No Data
No Data
New Life: 2024 Semi-Annual Report
New Life: 2024 Semi-Annual Report Summary
Xinlefu (301323.SZ) released its performance for the first half of the year, with a net income of 73.8057 million yuan, a growth of 21.36%.
Xinlaifu (301323.SZ) released its 2024 interim report, and during the reporting period, the company achieved revenue of 4...
Xinlaifu (301323.SZ): Has accumulated a repurchase of 1.18% of the shares.
On August 2nd, Gelunhui reported that up to July 31, 2024, the company had repurchased a total of 1,241,090 shares through a share buyback dedicated securities account under the method of centralized bidding transaction, accounting for 1.1829% of the total current share capital. The highest fill price was 32.98 yuan/share, the lowest fill price was 27.73 yuan/share, and the total amount of funds used was 37.2943 million yuan (excluding transaction costs).
Guangzhou Newlife New Material CO., LTD's (SZSE:301323) Biggest Owners Are Private Companies Who Got Richer After Stock Soared 12% Last Week
Sinfon Pharmaceutical Co., Ltd. (301323.SZ) will distribute a dividend of 4 yuan per share for the 2023 fiscal year, with the equity registration date on June 20.
On June 13th, Gelunhui announced that the company's 2023 annual equity distribution plan is based on a total number of 103,820,600 shares of existing total share capital minus 1,102,290.00 repurchased shares. All shareholders will receive RMB 4.000000 in cash (including tax) for every 10 shares held. The registration date for this equity distribution is June 20, 2024, and the ex-rights and ex-dividend date is June 21, 2024.
No Data